Indefinite Delivery Contract SPE2DU25D9537

The key details of this federal contract IDV award are as follows:

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, valued at $499,999,999 and valid through November 2026. This IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain.

The original solicitation was for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts, which are intended to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), United States Coast Guard, and U.S. Naval Fleet. The solicitation is expected to be issued in March 2024 and will remain open for 45 days, with multiple awards planned for separate regions to ensure resilience and access to vital pharmaceuticals during contingencies or natural disasters.